TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition

Benzinga Logo Benzinga • •By Vandana Singh
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition

Merck reported positive Phase 2 CADENCE study results for Winrevair in treating combined pulmonary hypertension, showing significant reduction in pulmonary vascular resistance and a consistent safety profile.

Insights
NVDA   neutral

Mentioned as a key competitor to AMD, previously outperformed AMD but now seeing slower growth


MRK   positive

Demonstrated promising clinical trial results for Winrevair, met primary study endpoint, planning Phase 3 development, and stock price increased by 4.70%